Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.
Latest News
Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?
For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.
At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.
We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.
Emalex Biosciences Announces First Patient Enrolled in Phase 2b Clinical Study to Evaluate the Efficacy and Safety of Ecopipam Tablets for the Treatment of Pediatric Patients with Tourette Syndrome
Emalex Biosciences Appoints Dr. Atul R. Mahableshwarkar as Senior Vice President of Drug Development
Emalex Biosciences Acquires Psyadon Pharmaceuticals To Develop Novel Treatment For Pediatric Tourette Syndrome
Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.
Latest News
Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?
For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.
At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.
We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
By emalexadmin |
Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.
Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?
For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.
At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.
We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
By emalexadmin |
Emalex Receives U.S. Patent for Orally Disintegrating Ecopipam Formulation
By emalexadmin |